Sun, May 19, 2013, 1:55 PM EDT - U.S. Markets closed
you are viewing a single comment's thread.
Byergo: LLY has been no ball of fire over the last six months but neither has MNKD. If MNKD's diabetes drug is superior to LLY's(the drugs' of both companies still in the test stage) why have both stocks underpreformed in the stock market?
That's why it's such a favorable time to buy MNKD right now.It is remarkably undervalued, unknown, and underappreciated relative to it's true market potential.And FDA approval should come literally any day.